Triple Negative Breast Cancer Treatment Options and Limitations: Future Outlook.
Obidiro O, Battogtokh G, Akala EO. · 2023
Read Triple Negative Breast Cancer Treatment Options and Limitations: Future Outlook. by Obidiro O, Battogtokh G, Akala EO. (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc10384267.txt.
Introduction
Obidiro, Battogtokh, and Akala reviewed care options in 2023 for a hard form of breast cancer. The form is called triple negative, since its cells lack three known drug targets. Those targets are two hormone sensors and the HER2 protein. Survival rates for this form lag behind other breast cancers.
Chemo drugs stay the most used treatment, often before or after surgery. Obidiro also covers immune therapy, targeted drugs, and beam therapy. Two flaws limit chemo: cancer cells learn to resist it, and it harms healthy cells too. The review points to tiny drug carriers, called nanoparticles, as a way past both flaws. Trials of such carriers form part of the future outlook.
Catalog record
| CREATOR | Obidiro O, Battogtokh G, Akala EO. |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 101 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Triple Negative Breast Cancer Treatment Options and Limitations: Future Outlook By Onyinyechi Obidiro, Gantumur Battogtokh, Emmanuel O. Akala, Rosaria Benedetti, Federica Sarno, Carmela Dell’Aversana, Donato Cappetta, Wouter Leonard Megchelenbrink Published in: Pharmaceutics DOI: 10.3390/pharmaceutics15071796 ABSTRACT Triple negative breast cancer (TNBC) has a negative expression of estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor receptors (HER2). The survival rate for TNBC is generally worse than other breast cancer subtypes. TNBC treatment has made significant advances, but certain limitations remain. Treatment for TNBC can be challenging since the disease has various molecular subtypes. A variety of treatment options are available, such as chemotherapy, immunotherapy, radiotherapy, and surgery. Chemotherapy is the most common of these options. TNBC is generally treated with systemic chemotherapy using drugs such as anthracyclines and taxanes in neoadjuvant or adjuvant settings. Developing resistance to anticancer drugs and off-target toxicity are the primary hindrances to chemotherapeutic solutions for cancer. It is imperative that researchers, clinicians, and pharmaceutical companies work together to develop effective treatment options for TNBC. Several studies have suggested nanotechnology as a potential solution to the problem of suboptimal TNBC treatment. In this review, we summarized possible treatment options for TNBC, including chemotherapy, immunotherapy, targeted therapy, combination therapy, and nanoparticle-based therapy, and some solutions for the treatment of TNBC in the future. Moreover, we gave general information about TNBC in terms of its characteristics and aggressiveness. 1. INTRODUCTION Cancer continues to be a growing menace to society; in one year, a mortality rate of 8.2 million was recorded worldwide [1]. Over 13.1 million people are expected to die from cancer globally by 2030, making it the leading cause of death after cardiovascular diseases [1,2]. Cancer can affect any part of the body, occurring in all genders [2]. Breast cancer is the most commonly diagnosed cancer among women and has surpassed lung cancer, with about 2.3 million cases yearly [3,4]. This situation calls for a comprehensive understanding of the disease and the development of improved therapeutics. Breast cancer is a multifactorial disease involving environmental, hormonal, genetic, and various lifestyle and nutritional factors. Hence, breast cancer patients experience various clinical, pathological, and molecular peculiarities [5]. The molecular subtypes of breast cancer are classified by the expression profile of the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). Triple negative breast cancer (TNBC) has low or no expression of estrogen receptors (ER), progesterone receptors (PR), and the human epidermal growth factor receptors (HER2; consequently, it does not respond to drugs that target these receptors [6,7,8,9] and there is currently no standardized TNBC treatment regimen. TNBC is characterized by a high level of cell invasiveness and visceral metastasis to organs, usually the brain, lungs, and liver (Figure 1), with an average survival time of 18 months [10,11]. TNBC is more likely to metastasize to the central nervous system and internal organs such as the liver, bones, and lungs. Patients with TNBC have a much shorter survival period once distant metastases have occurred [12]. TNBC is usually detected late in the body at the advanced stage [11,13]. It is more likely that TNBC is related to hereditary conditions than other breast cancer subtypes. In the American Cancer Society’s study of newly diagnosed breast cancer, 10% of patients had breast cancer gene 1 (BRCA1) and breast cancer gene 2 (BRCA2) mutations, whereas 35% of patients with TNBC carried a BRCA1 mutation, and 8% carried a BRCA2 mutation. There is a greater than one-third chance of developing TNBC among BRCA1 mutation carriers [14]. Typically, TNBC is diagnosed via imaging and immunohistochemistry (IHC), which are operator-dependent and time-consuming procedures [15]. To enhance the diagnostic efficiency of TNBC, rapid and advanced technologies such as immuno positron emission tomography (PET), nanobiosensor, circulating tumor nucleic acids (ctNAs), and blood-based liquid biopsy are essential [16]. Compared to other breast cancer subtypes, TNBC is the most immunogenic subtype with a limited treatment option [17]. TNBC is the most aggressive and heterogeneous of all breast cancer subtypes; hence it has been described as fatal [10,18,19]. Literature evidence indicates that it is reportedly the greatest cause of mortality in women [20,21]. TNBC accounts for 15–20% of all breast cancer. Population-based studies confirm that TNBC is prevalent in young pre-menopausal women under 40 years, African American, and Hispanic women of lower socioeconomic backgrounds [11,22,23,24]. Non-Hispanic African American women have a lower breast cancer incidence than non-Hispanic White women [25]. However, African American women have doubled triple-negative breast cancer incidence [26]. Possibly, this is due to the relatively low number of African American women receiving treatment recommended by guidelines. In addition, there is a difference in treatment outcomes between African American women and white women with TNBC. According to a population-based cohort study of 23,213 patients with TNBC, African American women were significantly more likely to die from breast cancer than white women [27]. The authors suggested that disparities in surgery and chemotherapy may contribute to this phenomenon. There have not been many new treatment methods developed for TNBC compared to other types of breast cancer due to the aggressive nature of this type of breast cancer [28]. Chemotherapy takes advantage of the high growth rate of tumor tissues. Angiogenesis inhibitors cut the blood flow to tumor tissues, and interference in the ribonucleic acid (RNA) messenger pathway causes apoptosis in the already impaired deoxyribonucleic acid (DNA) [11,29]. There is a tendency for TNBC tissues to express more epithelial growth factor receptor (EGFR) protein than other breast cancer subtypes, which makes them more resistant to conventional treatment [7]. Several inflammatory molecules, including tumor-associated macrophages (TAM), tumor-infiltrating lymphocytes (TILs), and cytokines, reduce the immune response to TNBC during chemotherapy, increasing the possibility of complications related to TNBC. Controlling these inflammatory molecules may improve patients’ overall and disease-free survival rates with TNBC. The manipulation of microRNAs (miRNA) in TNBC can reduce the risk of early relapse and metastasis by influencing cancer cell survival, proliferation, invasion, and metastasis [28]. TNBC is associated with chemoresistance due to the poor prognosis, relapse, and distal metastasis of TNBC [30]. In this review, we discuss the current options for TNBC treatment, their limitations, and future directions for TNBC treatment. 2. SUBTYPES OF TNBC TNBCs typically resemble basal-like breast cancer (BLBC) with overlapping gene expression characteristics [11]. Based on gene expression profiles, six TNBC subtypes, each with a different gene expression profile and ontology, were identified which are basal-like 1 (BL-1), basal-like 2 (BL-2), an immunomodulatory subtype (IM), a mesenchymal subtype (M), a mesenchymal stem-like subtype (MSL), and a luminal androgen receptor subtype (LAR) [28,31], (Figure 2). Despite this, most triple-negative breast cancers (80%) express markers of basal-associated cancer, including basal cytokeratin, vimentin, EGFR, and mutated BRCA1/2 [22]. The genetic variations among these subtypes of TNBC suggest individualized therapy rather than a generalized approach [32]. 2.1. Basal-like 1 and 2 Subtypes Approximately 75% of TNBCs are basal-like subtypes, so TNBC makes up the majority of these subtypes. A high level of DNA damage response is associated with the basal-like 1 subtype. According to studies, basal-like immune-suppressed subtypes of TNBC exhibit lower levels of B cell, T cell, and natural killer cells, resulting in worse prognoses. Generally, all BRCA1/2 mutations are associated with basal-like gene patterns.